Search Result

Results for "

excretion

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Amylases (1) Apoptosis (1) Biochemical Assay Reagents (1) Cytochrome P450 (1) Endogenous Metabolite (17) Glucosidase (1) HBV (1) Isotope-Labeled Compounds (1) Na+/Ca2+ Exchanger (3) NO Synthase (1) P-glycoprotein (1) Potassium Channel (1) Reactive Oxygen Species (1) SGLT (3) Small Interfering RNA (siRNA) (1) Src (1) URAT1 (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (3) Infection (1) Inflammation/Immunology (5) Metabolic Disease (27) Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0324

Cholic acid 4 Publications Verification	Endogenous Metabolite	Metabolic Disease
Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active .

HY-113409

3-Hydroxyisovaleric acid	Endogenous Metabolite	Metabolic Disease
3-Hydroxyisovaleric acid is a normal endogenous metabolite excreted in the urine. The urinary excretion of 3-hydroxyisovaleric acid is early and sensitive indicator of biotin deficiency .

HY-137339

Amitriptyline N-β-D-glucuronide

Others Others

Amitriptyline N-β-D-glucuronide is an ammonium glucuronide and an urinary excretion metabolite of amitriptyline .

Amitriptyline N-β-D-glucuronide	Others	Others
Amitriptyline N-β-D-glucuronide is an ammonium glucuronide and an urinary excretion metabolite of amitriptyline .

HY-111054

N-methyl-N-dithiocarboxyglucamine MDCG	Endogenous Metabolite	Inflammation/Immunology
N-methyl-N-dithiocarboxyglucamine (MDCG) mobilizes and promotes excretion of metallothione-bound ¹⁰⁹Cd. N-methyl-N-dithiocarboxyglucamine shows effects on acute and chronic Cd intoxication .

HY-N0324B

Cholic acid sodium hydrate	Endogenous Metabolite	Metabolic Disease
Cholic acid sodium hydrate is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. Cholic acid sodium hydrate facilitates fat absorption and cholesterol excretion. Cholic acid sodium hydrate is orally active .

HY-153972

URAT1&XO inhibitor 2	URAT1 Xanthine Oxidase	Metabolic Disease Inflammation/Immunology
URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC₅₀ of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a K_i value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia .

HY-N11562

Aristololactam II	Others	Others
Aristololactam II, a metabolite of Aristolochic acid II (AAII), is an excretion product found in the urine, which is considered to be detoxification metabolite of AAII .

HY-143712

Allolithocholic acid	Endogenous Metabolite	Metabolic Disease
Allolithocholic acid is a steroid acid could found in normal serum and feces. Allolithocholic acid facilitates excretion, absorption, and transport of fats and sterols in the intestine and liver .

HY-N0324A

Cholic acid sodium 4 Publications Verification Sodium cholate
Cholic acid sodium is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid sodium is orally active .

HY-B1724

Perflubron Perfluorooctyl bromide; 1-Bromoperfluorooctane; PFOB
Perflubron (Perfluorooctyl bromide) is a contrast medium for magnetic resonance imaging and sonography. Perflubron can be emulsified with egg phospholipids (EYP) and shows exceptionally fast excretion characteristics .

HY-76199

trans-4-Hydroxycyclohexanecarboxylic acid	Others	Metabolic Disease
trans-4-Hydroxycyclohexanecarboxylic acid is a substrate for cyclohexanecarboxylic acid production. trans-4-Hydroxycyclohexanecarboxylic acid is the by-product of intestinal bacterial metabolism via urinary excretion .

HY-126816

Atrazine mercapturate	Endogenous Metabolite	Others
Atrazine mercapturate is a metabolite of herbicide Atrazine (HY-N7091), which is detectable in urinary excretion. Atrazine mercapturate serve as an unambiguous confirmation of human exposure to Atrazine .

HY-N0324S

Cholic acid-d4	Endogenous Metabolite	Metabolic Disease
Cholic acid-d₄ is the deuterium labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.

HY-N0324S1

Cholic acid-d5	Endogenous Metabolite	Metabolic Disease
Cholic acid-d₅ is the deuterium labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.

HY-N0324S2

Cholic acid-13C	Endogenous Metabolite	Metabolic Disease
Cholic acid- ¹³C is the ¹³C-labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.

HY-B0373

Tiopronin	Others	Metabolic Disease
Tiopronin is a diffusible antioxidant, an antidote to heavy metal poisoning and a radioprotective agent. Tiopronin can control the rate of cystine precipitation and excretion and has the potential for cystinuria, rheumatoid arthritis and hepatic disorders .

HY-131060

CN128 hydrochloride

CN328
Others Others

CN128 hydrochloride (CN328) is an orally active and selective iron chelator. CN128 is used for the research of β-thalassemia .

CN128 hydrochloride CN328	Others	Others
CN128 hydrochloride (CN328) is an orally active and selective iron chelator. CN128 is used for the research of β-thalassemia .

HY-B0235

Trichlormethiazide	Others	Metabolic Disease
Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .

HY-B0235A

Trichlormethiazide sodium	Others	Metabolic Disease
Trichlormethiazide sodium is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide sodium increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .

HY-N0324R

Cholic acid (Standard)	Endogenous Metabolite	Metabolic Disease
Cholic acid (Standard) is the analytical standard of Cholic acid. This product is intended for research and analytical applications. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active .

HY-132613

Lumasiran sodium	Small Interfering RNA (siRNA)	Metabolic Disease
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .

HY-N10616

Pseudobaptigenin	Others	Metabolic Disease
Pseudobaptigenin is a flavonoid. Pseudobaptigenin shows very good anticataract activity. Pseudobaptigenin has good binding affinity for the inhibition of glycation against γ-crystallin protein. Pseudobaptigenin also has good ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) property .

HY-106570

Tripamide

Potassium Channel Metabolic Disease

Tripamide is an orally active sulfonamide-derived diuretic antihypertensive agent .

Tripamide	Potassium Channel	Metabolic Disease
Tripamide is an orally active sulfonamide-derived diuretic antihypertensive agent .

HY-B0373S1

Tiopronin-d3	Isotope-Labeled Compounds	Metabolic Disease
Tiopronin-d₃ is the deuterium labeled Tiopronin. Tiopronin is a diffusible antioxidant, an antidote to heavy metal poisoning and a radioprotective agent. Tiopronin can control the rate of cystine precipitation and excretion and has the potential for cystinuria, rheumatoid arthritis and hepatic disorders[1][2].

HY-111054A

N-methyl-N-dithiocarboxyglucamine sodium MDCG sodium	Endogenous Metabolite	Others
N-methyl-N-dithiocarboxyglucamine (MDCG) sodium mobilizes and promotes excretion of metallothionein-bound ¹⁰⁹Cd in mouse model. N-methyl-N-dithiocarboxyglucamine significantly lowers the Cd content of both the liver and kidney, which is organs most susceptible to Cd-induced toxicity .

HY-113420

11-Dehydro-thromboxane B2	Endogenous Metabolite	Metabolic Disease
11-Dehydro-thromboxane B2 is a platelet hemagglutinin. Thromboxane inhibition was assessed by urinary excretion levels of 11-Dehydro-thromboxane B2. 11-Dehydro-thromboxane B2 can be used in the study of atherosclerotic thrombosis .

HY-113377

L-Glyceric acid	Endogenous Metabolite	Metabolic Disease
L-Glyceric acid is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid excretion to distinguish PH1 from PH2 .

HY-113377A

L-Glyceric acid sodium	Endogenous Metabolite	Metabolic Disease
L-Glyceric acid sodium is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid sodium can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid sodium excretion to distinguish PH1 from PH2 .

HY-W035520

HBED dihydrochloride	Biochemical Assay Reagents	Others
HBED dihydrochloride is an orally active and hexadentate phenolic aminocarboxylate iron chelator. HBED refers to N, N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid, inducing iron excretion in primates. HBED dihydrochloride has the potential to be used as an alternative to desferriamine for iron chelation therapy .

HY-163301

Antitumor agent-139	Reactive Oxygen Species	Cancer
Antitumor agent-139 (compound 9b) is a liver - and mitochondria-targeting gold(I) complexe, and produces reactive oxygen species (ROS) and facilitates DNA excretion. Antitumor agent-139 inhibits tumor growth in a patient-derived xenograft model of hepatocellular carcinoma .

HY-10450

Dapagliflozin Maximum Cited Publications 31 Publications Verification BMS-512148	SGLT	Metabolic Disease Cancer
Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-113329

Guanidinoethyl sulfonate Taurocyamine	Endogenous Metabolite	Metabolic Disease
Guanidinoethyl sulfonate (Taurocyamine), a transport antagonist of taurine, induces much urinary taurine excretion with a resulting decrease in the tissue taurine content and readily produces taurine-deficient fetal rats in pregnant rats . Guanidinoethyl sulfonate, a structural analogue of taurine, acts as a competitive inhibitor of taurine transport .

HY-113465

Leukotriene E4 LTE4	Endogenous Metabolite	Inflammation/Immunology
Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.

HY-B0235R

Trichlormethiazide (Standard)	Others	Metabolic Disease
Trichlormethiazide (Standard) is the analytical standard of Trichlormethiazide. This product is intended for research and analytical applications. Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .

HY-122613

YM543 free base	SGLT	Metabolic Disease
YM543 free base is a potent and orally active sodium-glucose cotransporter (SGLT) 2 inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes .

HY-123298

Chrysotoxine	Src Akt Apoptosis	Cancer
Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research .

HY-113465S

Leukotriene E4-d5 LTE4-d₅	Endogenous Metabolite	Inflammation/Immunology
Leukotriene E4-d₅ is the deuterium labeled Leukotriene E4. Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.

HY-N4190

Britannilactone diacetate 1,6-O,O-Diacetylbritannilactone; Di-O-acetylbritannilactone	NO Synthase	Neurological Disease Inflammation/Immunology
Britannilactone diacetate (1,6-O,O-Diacetylbritannilactone; Compound 2) exhibits potential NO inhibition effect. Britannilactone diacetate exhibits activity against NO production induced by LPS in BV-2 microglial cells with the EC₅₀ value of 6.3 μM. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBB) penetration and absorption, distribution, metabolism, excretion, and toxicity (ADMET) property .

HY-124364

RO6889678	HBV Cytochrome P450	Infection Metabolic Disease
RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation .

HY-10450A

Dapagliflozin ((2S)-1,2-propanediol, hydrate) Maximum Cited Publications 31 Publications Verification BMS-512148 (2S)-1,2-propanediol, hydrate	SGLT	Metabolic Disease Cancer
Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .

HY-136182

YM-244769 dihydrochloride	Na+/Ca2+ Exchanger	Cardiovascular Disease Neurological Disease
YM-244769 dihydrochloride is a potent, selective and orally active Na ⁺/Ca ²⁺ exchanger (NCX) inhibitor. YM-244769 dihydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca ²⁺ entry mode), with IC₅₀s of 18 nM and 50 nM, respectively. YM-244769 dihydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 dihydrochloride can also increase urine volume and urinary excretion of electrolytes in mice .

HY-136182A

YM-244769	Na+/Ca2+ Exchanger	Cardiovascular Disease Neurological Disease
YM-244769 is a potent, selective and orally active Na ⁺/Ca ²⁺ exchanger (NCX) inhibitor. YM-244769 preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca ²⁺ entry mode), with IC₅₀s of 18 nM and 50 nM, respectively. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 can also increase urine volume and urinary excretion of electrolytes in mice .

HY-107659

YM-244769 hydrochloride	Na+/Ca2+ Exchanger	Cardiovascular Disease Neurological Disease
YM-244769 hydrochloride is a potent, selective and orally active Na ⁺/Ca ²⁺ exchanger (NCX) inhibitor. YM-244769 hydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca ²⁺ entry mode), with IC₅₀s of 18 nM and 50 nM, respectively. YM-244769 hydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 hydrochloride can also increase urine volume and urinary excretion of electrolytes in mice .

HY-162373

α-Amylase/α-Glucosidase-IN-10	Amylases Glucosidase P-glycoprotein	Metabolic Disease
α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC₅₀: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .

Cat. No.	Product Name

HY-L0086V

Specs HTS Compounds Library
208,518 compounds

A unique collection contains 208,670 diverse chemical compounds to pharmaceutical and biotechnology scientists for drug discovery.

Specs HTS Compounds Library	208,518 compounds
A unique collection contains 208,670 diverse chemical compounds to pharmaceutical and biotechnology scientists for drug discovery.

HY-L145

Antihypertensive Compound Library

481 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 481 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

HY-L047

Endocrinology Compound Library

869 compounds

The endocrine system is a chemical messenger system comprising feedback loops of the hormones released by internal glands of an organism directly into the circulatory system, regulating distant target organs. Hormones are chemicals that serve to communicate between organs and tissues for physiological regulation and behavioral activities. Hormones affect distant cells by binding to specific receptor proteins in the target cell, resulting in a change in cell function.

The endocrine system is concerned with the integration of developmental events proliferation, growth, and differentiation, and the psychological or behavioral activities of metabolism, growth and development, tissue function, sleep, digestion, respiration, excretion, mood, stress, lactation, movement, reproduction, and sensory perception caused by hormones. Irregulated hormone release, inappropriate response to signaling or lack of a gland can lead to endocrine disease.

MCE offers a unique collection of 869 endocrinology related compounds targeting varieties of hormone receptors such as thyroid hormone receptor, TSH receptor, GNRH receptor, adrenergic receptor, etc. MCE Endocrinology Compound Library is a useful tool for the discovery of endocrinology drugs.

Cat. No.	Product Name	Category	Target	Chemical Structure